Short answer:
There isn’t a generic Saxenda on the market today, and no firm date has been set for when one will become available. The generic is likely to appear sometime after the current patents on the drug and its weight‑loss formulation expire—most estimates put that window around 2026‑2027, but the exact timing depends on when a generic manufacturer files an application and the FDA approves it.
---
Why it’s still a brand‑name drug
| Issue | Detail |
|-------|--------|
| Active ingredient | Liraglutide – the same molecule used in the diabetes drug Victoza (and already available as generics for diabetes in many countries). |
| Formulation & dosage | Saxenda is a 3 mg/mL solution that delivers 3.0 mg/day, whereas the diabetes formulation is 0.6–1.8 mg/day. The different concentration and delivery schedule are protected by separate patents. |
| Patent landscape | The primary “composition‑of‑matter” patent for liraglutide expired in the early 2020s, but Novo Nordisk holds numerous method‑of‑use, formulation, and delivery‑device patents that keep Saxenda’s market exclusivity alive for a few more years. |
| Regulatory status | No generic application for Saxenda has been approved by the FDA as of 2024. A generic would need to demonstrate bioequivalence to the branded product and pass all safety and efficacy reviews. |
When could a generic appear?
1. Patent expiry
- Most of the critical Saxenda patents in the U.S. are expected to expire in 2026‑2027. Once those patents lapse, generic manufacturers are free to seek approval.
2. Generic filing and FDA review
- Even after the patents expire, a generic applicant must file a Biologics License Application (BLA) and wait for FDA review. That process can take 1–2 years, so a realistic window for a generic launch is late 2028 to 2030.
3. Market factors
- Novo Nordisk’s market share, the cost of developing a comparable delivery device, and competition from other GLP‑1 weight‑loss drugs (e.g., Wegovy) can influence how quickly a generic appears.
What this means for patients
- Current options – Until a generic is approved, Saxenda remains the sole brand‑name product for GLP‑1‑based weight loss in the U.S. (though the diabetes formulation can be used off‑label).
- Cost considerations – Insurance coverage and copay assistance programs may reduce costs, but a generic would likely cut the price significantly once available.
- Monitoring – If you’re on Saxenda, keep an eye on FDA announcements or press releases from Novo Nordisk and generic manufacturers. When a generic becomes available, your pharmacy or provider can help transition.
---
Bottom line
- No generic Saxenda today.
- Expected generic approval window: Late 2028–2030, following the expiration of current patents and FDA review.
- Stay informed: Check the FDA’s “Generic Drugs” page and watch for new drug application (NDA) filings from generic companies that might bring a Saxenda alternative to market.